The FDA has approved Nycomed and partner Forest Laboratories’ chronic obstructive pulmonary disease drug roflumilast, according to PharmaTimes.

The FDA approved Daliresp (roflumilast), marketed elsewhere as Daxas, as a treatment to reduce the risk of COPD exacerbations associated with chronic bronchitis. The once-daily oral drug is a selective phosphodiesterase-4 (PDE4) inhibitor and will be available to wholesalers in the second quarter.